CLINICAL PHARMACY PATHWAY ANALYSIS OF ANTIEMETIC DRUGS AND PROTON PUMP INHIBITORS
Objective To analyze the clinical pharmacy pathway effect of antiemetic drugs and proton pump inhibitors.Methods The study period was from January 2022 to February 2023,and a total of 300 cancer patients admitted to the Depart-ment of Oncology in our hospital were enrolled as the study objects.From January 2022 to July 2022,antiemetic drugs and proton pump inhibitors were used as routine interventions,and 150 patients were enrolled in the study.From August 2022 to February 2023,the clinical pharmacy pathway approach was applied to antiemetic drugs and proton pump inhibitors,and 150 patients were enrolled in the study,setting the group name after implementation.The effect of intervention in the two groups was analyzed.Re-sults After the implementation of antiemetic drugs and proton pump inhibitors per capita drug cost,sales amount,use intensity,frequency statistics were lower than before the implementation(P＜0.05);The incidence of irrational drug use and adverse reac-tions were lower after implementation than before implementation(P＜0.05).Before implementation,the majority of patients had moderate adverse reactions,but after implementation,the majority of patients had mild adverse reactions(P＜0.05).In terms of quality of life,the scores of physiological function,physiological function,general health,mental health,vitality,physical pain,emotional function and social function were higher after implementation than before implementation,and the data were different(P＜0.05).Conclusion Through clinical pharmacy pathway,it is helpful to improve the rational drug use effect of antiemetic drugs and proton pump inhibitors,and the adverse reactions of patients are less and the severity is less.
国家科技期刊平台
NSTL
万方数据
